首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1620347

全球紅色生物技術市場規模：按產品類型、按應用、按最終用戶、按地區、範圍和預測

Global Red Biotechnology Market Size By Product Type (Gene Recombinant Drugs, Human Vaccines), By Application (Pharmacogenomics, Gene Therapy), By End-User (Research Institutes, Biopharmaceutical Industries), By Geographic Scope And Forecast

出版日期: 2024年08月31日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

紅色生物技術市場規模及預測

2024年紅色生物技術市場規模為5,481.1億美元，預計到2031年將達到1,1411.7億美元，2024年至2031年複合年增長率為9.60%。紅色生物技術是生物技術的一個分支，專注於利用生物過程和生物體來開發創新藥物和治療方法。這個充滿活力的領域涵蓋了廣泛的活動，包括藥物發現和開發、生物製藥、疫苗、診斷、基因治療和組織工程。我們利用生物學方法來識別和開發針對各種疾病的新藥。

透過開發更有效率、更有效的治療方法，Red Biotechnology 可以幫助減少整體醫療保健支出。

例如，生物技術和工具的進步正在推動創新並擴大該領域的可能性。

該領域允許開發客製化治療方法，以滿足個別患者的特定需求，從而提高治療效果。

紅色生物技術的世界市場動態

塑造全球紅色生物技術市場的關鍵市場動態

主要市場驅動因子

慢性病盛行率增加

全球慢性病的增加增加了對紅色生物技術測試的需求。根據世界衛生組織 (WHO) 預測，到 2022 年，慢性病將佔全球死亡人數的 71%。這一趨勢推動了對先進診斷和治療解決方案的需求。

擴大研發投入：

研發投資的增加正在推動紅色生物測試的創新。美國國立衛生研究院（NIH）2023財政年度生物醫學研究預算達451億美元，較2022財年增加3.5%。資金的增加正在加速基因檢測和生物標記發現的進步。

個人化醫療的趨勢：

向個人化醫療的轉變正在主導生物技術測試領域。美國FDA將在2023年核准26種個人化藥物，佔所有新藥核准的39%。這一趨勢正在推動伴隨診斷和標靶治療的發展。

基因編輯技術的進展：

基因編輯技術的快速進步正在推動紅色生物技術測試市場的發展。根據美國國家人類基因組研究所預測，到2025年，全球CRISPR技術市場預計將達到53億美元。這些技術創新為基因檢測和治療開發開闢了新途徑。

主要問題

阻礙市場成長的監管障礙：

應對紅色生物技術相關的複雜監管環境可能是一項重大課題。遵守與藥物開發、臨床試驗和產品批准相關的法規既耗時又昂貴，阻礙了市場進入和成長。

阻礙創新的道德問題：

圍繞基因改造、幹細胞研究和生物技術其他方面的倫理考量可能會帶來課題和限制。解決這些問題並獲得公眾認可對於該領域的進步至關重要。

因技術限製而導致的產品開發課題：

儘管取得了重大進展，但紅色生物技術仍存在技術限制，包括擴大生產規模、確保產品一致性和克服免疫反應方面的課題。克服這些限制對於創新產品的商業化至關重要。

高成本阻礙市場滲透：

紅色生物技術產品的開發和商業化成本高昂，需要在研究、開發和製造方面進行大量投資。這些高昂的成本可能會阻礙市場滲透並限制患者獲得創新治療。

主要趨勢

對現場偵測的需求不斷增加：

對快速現場檢測的需求不斷增長正在推動 Red Biotechnology 的創新。美國醫療保險和醫療補助服務中心報告稱，從 2019 年到 2023 年，CLIA 豁免檢測設施數量增加了 32%。這一趨勢正在推動便攜式且易於使用的診斷設備的發展。

推動政府措施與支持政策：

政府措施和支持政策正在推動紅色生物檢測市場的發展。歐盟委員會已為 "地平線歐洲" （2021-2027）撥款955億歐元，其中大部分將用於健康研究。這些努力正在促進合作研究並加速市場成長。

擴大採用下一代定序儀 (NGS)：

擴大採用下一代定序正在推動紅色生物技術測試的成長。根據國家生物技術資訊中心預測，2023年全球NGS市場規模達63億美元。這項技術正在徹底改變基因檢測和疾病診斷。

越來越重視生物標記的發現：

對生物標誌物發現的日益關注正在推動紅色生物技術測試的進步。 FDA 報告稱，從 2020 年到 2023 年，與生物標記相關的藥物批准申請增加了 40%。這一趨勢正在推動新型診斷工具和標靶治療的發展。

Red Biotechnology Market size was valued at USD 548.11 Billion in 2024 and is projected to reach USD 1141.17 Billion by 2031 , growing at a CAGR of 9.60% from 2024 to 2031. Red biotechnology, a specialized branch of biotechnology, focuses on leveraging biological processes and organisms to develop innovative medical products and treatments. This dynamic field encompasses a wide spectrum of activities, including drug discovery and development, biopharmaceuticals, vaccines, diagnostics, gene therapy, and tissue engineering. Employing biological techniques to identify and develop novel drugs for a diverse range of diseases.

By developing more efficient and effective treatments, red biotechnology can contribute to reducing overall healthcare expenditures.

For instance, ingoing advancements in biotechnology techniques and tools are driving innovation and expanding the possibilities within this field.

The field enables the development of tailored therapies that address the specific needs of individual patients, enhancing treatment efficacy.

Global Red Biotechnology Market Dynamics

The key market dynamics that are shaping the global red biotechnology market include:

Key Market Drivers

Rising Prevalence of Chronic Diseases

: The increasing incidence of chronic diseases worldwide is propelling the demand for red biotechnology testing. According to the World Health Organization, chronic diseases accounted for 71% of global deaths in 2022. This trend is driving the need for advanced diagnostic and therapeutic solutions.

Growing Investments in R&D:

Escalating investments in research and development are fueling innovations in red biotechnology testing. The National Institutes of Health (NIH) budget for biomedical research reached $45.1 billion in fiscal year 2023, a 3.5% increase from 2022. This funding boost is accelerating advancements in genetic testing and biomarker discovery.

Dominating Trend of Personalized Medicine:

The shift towards personalized medicine is dominating the red biotechnology testing landscape. The U.S. FDA approved 26 personalized medicines in 2023, representing 39% of all new drug approvals. This trend is driving the development of companion diagnostics and targeted therapies.

Propelling Advancements in Gene Editing Technologies:

Rapid advancements in gene editing technologies are propelling the red biotechnology testing market forward. The global CRISPR technology market is projected to reach $5.3 billion by 2025, according to the National Human Genome Research Institute. These innovations are opening new avenues for genetic testing and therapy development.

Key Challenges:

Regulatory Hurdles Hindering Market Growth:

Navigating the complex regulatory landscape associated with red biotechnology can be a significant challenge. Compliance with regulations related to drug development, clinical trials, and product approval can be time-consuming and costly, hindering market entry and growth.

Ethical Concerns Hampering Innovation:

Ethical considerations surrounding genetic engineering, stem cell research, and other aspects of red biotechnology can create challenges and limitations. Addressing these concerns and obtaining public acceptance is essential for the advancement of the field.

Technological Limitations Challenging Product Development:

Despite significant advancements, there are still technological limitations in red biotechnology, such as challenges in scaling up production, ensuring product consistency, and overcoming immune responses. Overcoming these limitations is crucial for the commercialization of innovative products.

High Costs Obstructing Market Penetration:

The development and commercialization of red biotechnology products can be expensive, requiring substantial investments in research, development, and manufacturing. These high costs can limit market penetration and access to innovative treatments for patients.

Key Trends

Rising Demand for Point-of-Care Testing:

The growing demand for rapid, point-of-care testing is driving innovation in red biotechnology. The U.S. Centers for Medicare & Medicaid Services reported a 32% increase in CLIA-waived testing facilities from 2019 to 2023. This trend is fostering the development of portable and user-friendly diagnostic devices.

Propelling Government Initiatives and Supportive Policies:

Government initiatives and supportive policies are propelling the red biotechnology testing market. The European Commission allocated €95.5 billion for Horizon Europe (2021-2027), with a significant portion dedicated to health research. These initiatives are fostering collaborations and accelerating market growth.

Growing Adoption of Next-Generation Sequencing (NGS):

The increasing adoption of Next-Generation Sequencing is driving growth in red biotechnology testing. The global NGS market size was valued at $6.3 billion in 2023, according to the National Center for Biotechnology Information. This technology is revolutionizing genetic testing and disease diagnosis.

Rising Focus on Biomarker Discovery:

The escalating focus on biomarker discovery is propelling advancements in red biotechnology testing. The FDA reported a 40% increase in biomarker-related submissions for drug approvals from 2020 to 2023. This trend is driving the development of novel diagnostic tools and targeted therapies.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Red Biotechnology Market Regional Analysis

Here is a more detailed regional analysis of the global red biotechnology market:

North America

North America dominates the global red biotechnology market, accounting for the largest share due to its advanced healthcare infrastructure and robust research ecosystem.

According to the National Institutes of Health (NIH), the U.S. invested $45.1 billion in biomedical research in fiscal year 2023, fueling innovation in the sector.

This substantial funding has led to significant advancements in areas such as gene therapy and personalized medicine.

For instance, in February 15, 2024, Moderna announced the expansion of its mRNA pipeline, including 15 new programs in rare diseases and oncology, further solidifying North America's leadership in red biotechnology.

The region's market dominance is also driven by a high prevalence of chronic diseases and a supportive regulatory environment.

The Centers for Disease Control and Prevention (CDC) reported that 6 in 10 adults in the U.S. have a chronic disease as of 2023, creating a strong demand for innovative biotechnology solutions.

This demand is met by cutting-edge research and development efforts from industry leaders.

For instance, on September 8, 2023, Pfizer received FDA approval for its gene therapy treatment for hemophilia B, marking a significant milestone in red biotechnology applications and reinforcing North America's position at the forefront of the global market.

Asia Pacific

Asia Pacific is poised to emerge as the fastest-growing region in the global red biotechnology market during the forecast period, attributable by the by rapidly aging populations, increasing prevalence of chronic diseases, and rising disposable incomes.

According to the World Health Organization's Western Pacific Region office, healthcare expenditure in the region is projected to increase by 7.5% annually through 2025, driving demand for advanced biotechnology solutions.

For instance, in March 10, 2024, Takeda Pharmaceutical Company announced a $600 million investment to expand its biologics manufacturing capacity in Singapore, reinforcing the region's position as a key hub for red biotechnology.

The region's growth is further propelled by supportive government initiatives and improving healthcare infrastructure.

China's National Medical Products Administration (NMPA) reported a 35% increase in innovative medical device approvals in 2023 compared to the previous year, indicating a favorable regulatory environment for biotechnology advancements.

in addition to this, the emerging markets like India and South Korea are witnessing rapid adoption of personalized medicine approaches. For instance, in July 5, 2023, Samsung Biologics unveiled its new R&D Center in Songdo, South Korea, focusing on developing novel biologics and biosimilars to address unmet medical needs in the Asia Pacific region.

Global Red Biotechnology Market: Segmentation Analysis

The Global Red Biotechnology Market is segmented based on By Product Type, By Application, By End-User, and Geography.

Red Biotechnology Market, By Product Type

Monoclonal Antibodies
Polyclonal Antibodies
Recombinant
Proteins Vaccines
Others

Based on Product Type, the Global Red Biotechnology Market is bifurcated into Monoclonal Antibodies, Polyclonal Antibodies, Recombinant, Proteins Vaccines, Others. The monoclonal antibodies segment is currently dominating the global red biotechnology market, driven by their high specificity, sensitivity, and versatility. However, the recombinant proteins segment is growing at a rapid CAGR within the global red biotechnology market, fueled by advancements in genetic engineering and protein production technologies.

Red Biotechnology Market, By Application

Pharmacogenomics
Biopharmaceutical Production
Gene Therapy
Genetic Testing

Based on Application, the Global Red Biotechnology Market is bifurcated into Pharmacogenomics, Biopharmaceutical Production, Gene Therapy, Genetic Testing. The biopharmaceutical production segment is currently dominating the red biotechnology market, driven by the increasing demand for new and innovative drugs to treat various diseases. However, the gene therapy segment is experiencing rapid growth, fueled by advancements in gene editing technologies and the increasing potential of gene therapy to treat genetic disorders.

Red Biotechnology Market, By End-User

Research Institutes
CMOs & CROs
Biopharmaceutical Industries
Others

Based on End-User, the Global Red Biotechnology Market is bifurcated into Hospitals, Clinics, Insurance Companies, Government, Others. The biopharmaceutical industry is currently dominating the red biotechnology market, driven by the increasing demand for biologics in the treatment of chronic diseases and the rising investments in research and development by major pharmaceutical companies. However, the contract manufacturing organizations (CMOs) and contract research organizations (CROs) segment is experiencing rapid growth. These organizations provide specialized services to biopharmaceutical companies, such as manufacturing, clinical trials, and regulatory affairs.

Red Biotechnology Market, By Geography

North America
Europe
Asia Pacific
Rest of the world

Based on Geography, the Global Red Biotechnology Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America dominates the global red biotechnology market, accounting for the largest share due to its advanced healthcare infrastructure and robust research ecosystem. However, the Asia Pacific is poised to emerge as the fastest-growing region in the global red biotechnology market during the forecast period, attributable by the by rapidly aging populations, increasing prevalence of chronic diseases, and rising disposable incomes.

Key Players

The "Global Red Biotechnology Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Hoffmann-La Roche, Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Pfizer, Inc. , Biogen Inc. , Amgen Inc. and AstraZeneca Plc. and etc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Red Biotechnology Market Key Developments

In June 2022, CRISPR-Combo enables the editing of many genes in plants while modifying the expression of other genes, according to research from the University of Maryland's College of Agriculture and Natural Resources.
In September 2022, the US-FDA approved SKYSONA (elivaldogene autotemcel), often referred to as Eli-cel, in September 2022 for Bluebird Bio, Inc. to decrease the progression of neurologic deterioration in boys with early, active cerebral adrenoleukodystrophy (CALD) aged 4-17.

1 INTRODUCTION OF GLOBAL RED BIOTECHNOLOGY MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
3.5 Market attractiveness

4 GLOBAL RED BIOTECHNOLOGY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL RED BIOTECHNOLOGY MARKET, BY PRODUCT TYPE

5.1 Overview
5.2 Monoclonal Antibodies
5.3 Polyclonal Antibodies
5.4 Recombinant
5.5 Protein Vaccines
5.6 Cell-based Immunotherapy Products
5.7 Gene Therapy Products
5.8 Cell Therapy Products
5.9Tissue-engineered Products
5.10 Stem Cells
5.11 Cell Culture
5.12 Viral Vector
5.13 Enzymes
5.14 Kits and Reagents
5.15 Animal Models
5.16 Molecular Diagnostics
5.17 Others

6 GLOBAL RED BIOTECHNOLOGY MARKET, BY APPLICATION

6.1 Overview
6.2 Pharmacogenomics
6.3 Biopharmaceutical Production
6.4 Gene Therapy
6.5 Genetic Testing

7 GLOBAL RED BIOTECHNOLOGY MARKET, BY END USER

7.1 Overview
7.2 Research Institutes
7.3 CMOs & CROs
7.4 Biopharmaceutical Industries
7.5 Others

8 GLOBAL RED BIOTECHNOLOGY MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL RED BIOTECHNOLOGY MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies
9.4 ACE Matrix

10 COMPANY PROFILES

10.1 Amgen
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Gilead Sciences
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 AbbVie
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Johnson & Johnson
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Pfizer
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Merck & Co.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Roche
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Novartis
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Bristol Myers Squibb
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Takeda Pharmaceutical Company Limited
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments